Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jul;15(8):874-85.
doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16.

High-dose Chemotherapy Plus Autologous Stem-Cell Transplantation as Consolidation Therapy in Patients With Relapsed Multiple Myeloma After Previous Autologous Stem-Cell Transplantation (NCRI Myeloma X Relapse [Intensive Trial]): A Randomised, Open-Label, Phase 3 Trial

Affiliations
Clinical Trial

High-dose Chemotherapy Plus Autologous Stem-Cell Transplantation as Consolidation Therapy in Patients With Relapsed Multiple Myeloma After Previous Autologous Stem-Cell Transplantation (NCRI Myeloma X Relapse [Intensive Trial]): A Randomised, Open-Label, Phase 3 Trial

Gordon Cook et al. Lancet Oncol. .

Erratum in

  • Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text

Abstract

Background: Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT.

Methods: This multicentre, randomised, open-label, phase 3 study recruited patients aged at least 18 years with multiple myeloma who needed treatment for first progressive or relapsed disease at least 18 months after a previous ASCT from 51 centres across the UK. Before randomisation, eligible patients received bortezomib, doxorubicin, and dexamethasone (PAD) induction therapy and then underwent peripheral blood stem-cell mobilisation and harvesting if applicable. Eligible patients (with adequate stem-cell harvest) were randomly assigned (1:1), using an automated telephone randomisation line, to either high-dose melphalan 200 mg/m(2) plus salvage ASCT or oral cyclophosphamide (400mg/m(2) per week for 12 weeks). Randomisation was stratified by length of first remission or plateau and response to PAD re-induction therapy. The primary endpoint was time to disease progression, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00747877, and EudraCT, number 2006-005890-24.

Findings: Between April 16, 2008, and Nov 19, 2012, 297 patients were registered, of whom 293 received PAD re-induction therapy. Between Aug 26, 2008, and Nov 16, 2012, 174 patients with sufficient PBSCs were randomised to salvage ASCT (n=89) or cyclophosphamide (n=85). After a median follow-up of 31 months (IQR 19-42), median time to progression was significantly longer in the salvage ASCT than in the cyclophosphamide group (19 months [95% CI 16-25] vs 11 months [9-12]; hazard ratio 0·36 [95% CI 0·25-0·53]; p<0·0001). Frequently reported (in >10% of patients) grade 3-4 adverse events with PAD induction, salvage ASCT, and cyclophosphamide were: neutropenia (125 [43%] of 293 patients after PAD, and 63 [76%] of 83 patients in the salvage ASCT group vs 11 [13%] of 84 patients in the cyclophosphamide group), thrombocytopenia (150 [51%] after PAD, and 60 [72%] vs four [5%], respectively), and peripheral neuropathy (35 [12%] after PAD, and none vs none, respectively).

Interpretation: This study provides evidence for the improved efficacy of high-dose melphalan plus salvage ASCT when compared with cyclophosphamide in patients with relapsed multiple myeloma eligible for intensive therapy, which might help to guide clinical decisions regarding the management of such patients.

Funding: Cancer Research UK.

Comment in

Similar articles

See all similar articles

Cited by 33 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback